Steinia Lewis
Medical · Layton, UTNPI 1295187615
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 169 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 18 manufacturers, the largest accounting for just 13.2% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2024 at $1,179 and has fallen 56.5% since, to $513 in 2025.
Across 169 payments — averaging $18.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$418
- Johnson & Johnson$405
- Teva Pharmaceuticals USA, Inc.$404
- Neurocrine Biosciences, Inc.$306
- AbbVie$259
- Vanda Pharmaceuticals Inc.$234
- plus $1K from 12 others
What the payments were for
- Food & beverage$3,180100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 20 | $418 |
| Johnson & Johnson | 23 | $405 |
| Teva Pharmaceuticals USA, Inc. | 27 | $404 |
| Neurocrine Biosciences, Inc. | 15 | $306 |
| AbbVie | 13 | $259 |
| Vanda Pharmaceuticals Inc. | 9 | $234 |
| Ironshore Pharmaceuticals Inc. | 10 | $195 |
| Axsome Therapeutics, Inc. | 9 | $176 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $165 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 10 | $165 |
| Alkermes, Inc. | 7 | $129 |
| Lundbeck LLC | 7 | $119 |
| Biogen | 3 | $56 |
| Collegium Pharmaceutical, Inc. | 3 | $53 |
| Tris Pharma Inc | 2 | $33 |
| Indivior Inc. | 1 | $23 |
| Acadia Pharmaceuticals Inc | 1 | $21 |
| Idorsia Pharmaceuticals US Inc | 1 | $19 |
How this compares
$3,180 in reported general payments places this provider in the 75th percentile of 263 medical providers in Utah.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lurasidone Hcl | 12 | $552 |
| Alprazolam | 11 | $151 |
| Clonazepam | 12 | $29 |
Paid to pharmacies, not to this prescriber.
Other medical in Layton
- Val WarnerLayton$51K
- Mont RobinsLayton$3K
- Elisa WilcoxSalt Lake City$178K
- Viet leSalt Lake City$42K
- Carmelo DiazSalt Lake City$35K
- Shari CombeSalt Lake City$22K
- Kelly MikesellOgden$19K
- Jennifer CoombsSlc$12K
- Brandon HansenRiverton$10K
- Daniel CorryCedar City$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.